Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 61.78% is 1903% above its 5-year average of -3.43%, near the high end of its 5-year range (-43.62%–71.46%).
50.46% above its 12-month average of 41.06%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 3.32%.
RETURN ON ASSETS (ROA)
61.78%
RETURN ON ASSETS (ROA) AVG TTM
41.06%
RETURN ON ASSETS (ROA) AVG 3Y
4.27%
RETURN ON ASSETS (ROA) AVG 5Y
-3.43%
RETURN ON ASSETS (ROA) AVG 10Y
-28.13%
RETURN ON ASSETS (ROA) AVG 15Y
-31.12%
RETURN ON ASSETS (ROA) AVG 20Y
-41.18%
CURRENT VS TTM AVG
+50.46%
CURRENT VS 3Y AVG
+1345.15%
CURRENT VS 5Y AVG
+1902.92%
CURRENT VS 10Y AVG
+319.61%
CURRENT VS 15Y AVG
+298.51%
CURRENT VS 20Y AVG
+250.03%
SECTOR MEDIAN · HEALTHCARE
-30.94%
median of 765 covered companies
CURRENT VS SECTOR MEDIAN
+299.68%
vs the sector median at left
Rigel Pharmaceuticals, Inc.
Market Cap
$873.58M
Return on Assets (ROA)
61.78%
TTM Avg
41.06%
3Y Avg
4.27%
5Y Avg
-3.43%
Market Cap
$871.11M
Return on Assets (ROA)
-22.62%
TTM Avg
-55.95%
3Y Avg
-57.94%
5Y Avg
-46.38%
Market Cap
$865.55M
Return on Assets (ROA)
-5.88%
TTM Avg
-10.67%
3Y Avg
-19.76%
5Y Avg
-21.39%
Market Cap
$885.96M
Return on Assets (ROA)
55.85%
TTM Avg
-44.25%
3Y Avg
-43.62%
5Y Avg
-43.05%
Market Cap
$857.96M
Return on Assets (ROA)
-135.59%
TTM Avg
-77.84%
3Y Avg
-48.75%
5Y Avg
-48.75%
Market Cap
$853.75M
Return on Assets (ROA)
-18.34%
TTM Avg
-25.78%
3Y Avg
-11.37%
5Y Avg
4.46%
Market Cap
$842.26M
Return on Assets (ROA)
-23.15%
TTM Avg
-12.59%
3Y Avg
-25.36%
5Y Avg
-32.38%
Market Cap
$838.62M
Return on Assets (ROA)
-17.48%
TTM Avg
-47.13%
3Y Avg
-32.40%
5Y Avg
-21.92%
Market Cap
$900.62M
Return on Assets (ROA)
8.09%
TTM Avg
-0.64%
3Y Avg
-8.03%
5Y Avg
-4.54%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rigel Pharmaceuticals, Inc. (RIGL) | $873.58M | 61.78% | 41.06% | 4.27% | -3.43% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $871.11M | -22.62% | -55.95% | -57.94% | -46.38% |
| SI-BONE, Inc. (SIBN)vs › | $865.55M | -5.88% | -10.67% | -19.76% | -21.39% |
| Arbutus Biopharma Corp (ABUS)vs › | $885.96M | 55.85% | -44.25% | -43.62% | -43.05% |
| SL Science Holding Ltd (SLBT)vs › | $857.96M | -135.59% | -77.84% | -48.75% | -48.75% |
| QuidelOrtho Corporation (QDEL)vs › | $853.75M | -18.34% | -25.78% | -11.37% | 4.46% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $842.26M | -23.15% | -12.59% | -25.36% | -32.38% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | -17.48% | -47.13% | -32.40% | -21.92% |
| Bioventus Inc. (BVS)vs › | $900.62M | 8.09% | -0.64% | -8.03% | -4.54% |
| Alumis Inc. (ALMS)vs › | $840.12M | -78.30% | -72.68% | -105.45% | -105.45% |
ROA
61.8%
ROE
75.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 71.46% |
| 2024-12-31 | 10.66% |
| 2023-12-31 | -21.40% |
| 2022-12-31 | -43.62% |
| 2021-12-31 | -10.71% |
| 2020-12-31 | -26.95% |
| 2019-12-31 | -45.09% |
| 2018-12-31 | -50.67% |
| 2017-12-31 | -65.48% |
| 2016-12-31 | -88.59% |
| 2015-12-31 | -39.06% |
| 2014-12-31 | -58.98% |
| 2013-12-31 | -39.38% |
| 2012-12-31 | -31.88% |
| 2011-12-31 | -33.44% |
| 2010-12-31 | 20.30% |
| 2009-12-31 | -79.26% |
| 2008-12-31 | -92.00% |
| 2007-12-31 | -64.14% |
| 2006-12-31 | -33.24% |
| 2005-12-31 | -30.65% |
| 2004-12-31 | -71.37% |
| 2003-12-31 | -74.20% |
| 2002-12-31 | -83.51% |
| 2001-12-31 | -51.25% |
| 2000-12-31 | -39.46% |
| 1999-12-31 | -72.03% |
